Sydney, June 18, 2026, 07:03 AEST
- Cochlear finished at A$111.32 on Wednesday, gaining 4.17%. The stock was up 8.46% over the past week. Yahoo Finance
- S&P/ASX 200 rose 0.54% to close at 8,966.30 on Wednesday. ASX standard trading hours are from about 09:59:45 to 16:00 Sydney time. Investing
- Cochlear’s earnings downgrade from April is still weighing after the company trimmed its FY26 underlying profit forecast to A$290 million-A$330 million. Reuters
Cochlear Ltd is looking at a small bounce in Thursday’s Sydney pre-open after closing up 4.17% at A$111.32 on Wednesday. That was the hearing-implant maker’s best finish since the start of June.
Cochlear is still deep in the red, despite its recent climb. The stock is off 57.35% for 2026 and trading 65.15% under its 12-month peak of A$319.42. It’s bounced 23.69% from the late-April low at A$90.00. Intelligent Investor
Cochlear makes implantable hearing devices and sound processor upgrades. Investors used to see it as a defensive growth stock, but that view has faltered since Cochlear warned on weaker demand in developed markets and flagged that turmoil in the Middle East could hit its fourth-quarter sales. Reuters
Healthcare rebounded again. CSL added 0.51% to finish at A$106.79, ResMed’s ASX CDI moved up 0.58% to A$27.55, both providing some support for Cochlear. The gains gave the advance a broader sector lift beyond just company news. Intelligent Investor
Cochlear’s earnings guidance took a big cut in April. The company now sees FY26 underlying net profit at A$290 million to A$330 million, well below its previous range of A$435 million to A$460 million. Cochlear pointed to weaker developed-market implant sales, unrest in the Middle East, squeezed margins, restructuring charges, and a stronger Australian dollar. Constant currency, or CC, removes the impact of exchange rates. CEO Dig Howitt said adult and senior hearing loss is still seen as a “discretionary intervention.” He also said Cochlear remains “confident of our market leadership” as more people adopt the Nucleus Nexa system. Cochlear
Analysts remain wary. In April, Shane Ponraj at Morningstar said “the market was blindsided” by the downgrade. He slashed his fair value estimate for Cochlear by 51% to A$110 and sees “lower earnings growth for longer.” Morningstar
UBS cut its target price on Cochlear to A$106 from A$109, sticking with a Neutral call, according to a Tuesday note quoted by The Bull. The broker flagged risks tied to the Middle East, U.S. payers and Western European operating problems. Cochlear’s shares ended Wednesday just above the new target, leaving little buffer if results slip. The Bull
But any bounce might stall if delayed implant sales end up unrealized, or if hospitals, U.S. insurance denials, and issues in Europe keep dragging into FY27. Guidance is another watch point—a wide or cautious forecast at the next update could see bargain hunters flip to sellers fast.
Cochlear’s next full-year results come out Aug. 18. Before then, the stock isn’t being bought for a clear turnaround. Most of the trade is still on whether April’s profit warning is already in the price. Cochlear
